However, the popular anti-inflammatory drug was linked to at least one other clinical benefit cardiologists should know about. 

“Patients can safely continue oral intake until the time of the procedure, improving their satisfaction and comfort without adverse events,” researchers wrote.

Improving care for patients with cardiac amyloidosis has emerged as one of the hottest topics in cardiology. Pfizer helped kickstart that trend in 2019 when it gained FDA approval for two separate medications for the rare, but potentially fatal disease. 

Researchers in India performed TAVR on two relatively young patients with a preexisting mechanical mitral valve, sharing their experience in a new case report. The group highlighted the importance of planning ahead.

Anne Kroman, DO, PhD, noted that early, aggressive treatment is critical when EP leads need to be removed. 

New guidelines from the American Society of Echocardiography, made in collaboration with the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography, represent an update of the group's original recommendations from 2009.

According to CEO Sabine Bois, a veteran of the medical device industry, this approval represents a "significant leap forward" in the company's commitment to heart patients. 

Advanced AI models can evaluate a patient's heart failure risk using 12-lead ECG data—but there is still some room for improvement.